{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:50:16Z","timestamp":1762980616898,"version":"build-2065373602"},"reference-count":70,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T00:00:00Z","timestamp":1537833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hellenic Journal of Cardiology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.hjc.2018.09.004","type":"journal-article","created":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T23:42:57Z","timestamp":1538178177000},"page":"152-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Late-onset cardiomyopathy among survivors of childhood lymphoma treated with anthracyclines: a systematic review"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3462-4968","authenticated-orcid":false,"given":"Despoina-Rafailia","family":"Benetou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7045-4687","authenticated-orcid":false,"given":"Evangelos","family":"Stergianos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Geropeppa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erato","family":"Ntinopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Tzanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apostolos","family":"Pourtsidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas C.","family":"Petropoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marios K.","family":"Georgakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Tousoulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni Th","family":"Petridou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10125","key":"10.1016\/j.hjc.2018.09.004_bib1","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.hjc.2018.09.004_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2017.05.005","volume":"81","author":"Ferme","year":"2017","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.hjc.2018.09.004_bib3","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.hjc.2016.12.003","article-title":"Cardiac complications in cancer treatment - A review","volume":"58","author":"Li","year":"2017","journal-title":"Hellenic J Cardiol"},{"issue":"1","key":"10.1016\/j.hjc.2018.09.004_bib4","first-page":"8","article-title":"Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management","volume":"1","author":"Shakir","year":"2009","journal-title":"J\u00a0Clin Med Res"},{"issue":"4","key":"10.1016\/j.hjc.2018.09.004_bib5","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.1997.15.4.1544","article-title":"Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience","volume":"15","author":"Krischer","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.hjc.2018.09.004_bib6","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/eurheartj\/ehs181","article-title":"Cancer drugs and the heart: importance and management","volume":"34","author":"Suter","year":"2013","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.hjc.2018.09.004_bib7","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.amjcard.2014.04.055","article-title":"Left ventricular function in long-term survivors of childhood lymphoma","volume":"114","author":"Christiansen","year":"2014","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.hjc.2018.09.004_bib8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0360-3016(00)00647-7","article-title":"The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin's disease: University of Minnesota experience","volume":"48","author":"Lee","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.hjc.2018.09.004_bib9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.7326\/M15-0424","article-title":"Cardiac Outcomes in Adult Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy: A Cross-sectional Study","volume":"164","author":"Mulrooney","year":"2016","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.hjc.2018.09.004_bib10","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/mpo.1226","article-title":"Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: A report from the Children's Cancer Group","volume":"37","author":"Sposto","year":"2001","journal-title":"Med Pediatr Oncol"},{"issue":"10","key":"10.1016\/j.hjc.2018.09.004_bib11","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1161\/CIRCULATIONAHA.116.024811","article-title":"Population-based long-term cardiac-specific mortality among 34 489 five-year survivors of childhood cancer in Great Britain","volume":"135","author":"Fidler","year":"2017","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.hjc.2018.09.004_bib12","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"3","key":"10.1016\/j.hjc.2018.09.004_bib13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3109\/08880018.2013.851753","article-title":"Are cardiac magnetic resonance imaging and radionuclide ventriculography good options against echocardiography for evaluation of anthracycline induced chronic cardiotoxicity in childhood cancer survivors?","volume":"31","author":"Basar","year":"2014","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.hjc.2018.09.004_bib14","doi-asserted-by":"crossref","first-page":"513219","DOI":"10.1155\/2015\/513219","article-title":"NT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivors","volume":"2015","author":"Zidan","year":"2015","journal-title":"Dis Markers"},{"issue":"4","key":"10.1016\/j.hjc.2018.09.004_bib15","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0360-3016(96)00295-7","article-title":"Symptomatic coronary artery disease after mantle irradiation for Hodgkin's disease","volume":"36","author":"King","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.hjc.2018.09.004_bib16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1040-8428(97)10007-5","article-title":"Anthracycline-induced cardiotoxicity in children and young adults","volume":"27","author":"Giantris","year":"1998","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"10.1016\/j.hjc.2018.09.004_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"year":"2011","series-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","key":"10.1016\/j.hjc.2018.09.004_bib18"},{"issue":"3","key":"10.1016\/j.hjc.2018.09.004_bib19","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1200\/JCO.2006.08.4772","article-title":"Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease","volume":"25","author":"Donaldson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.hjc.2018.09.004_bib20","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1200\/JCO.1993.11.7.1208","article-title":"Cardiac disease following treatment of Hodgkin's disease in children and adolescents","volume":"11","author":"Hancock","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hjc.2018.09.004_bib21","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1200\/JCO.1993.11.1.100","article-title":"Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease","volume":"11","author":"Hudson","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.hjc.2018.09.004_bib22","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1200\/JCO.1994.12.10.2160","article-title":"ABVD\/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: the Stanford experience","volume":"12","author":"Hunger","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hjc.2018.09.004_bib23","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1200\/JCO.2009.25.2627","article-title":"Evaluation of coronary artery disease by computed tomography angiography in patients treated for childhood Hodgkin's lymphoma","volume":"28","author":"Kupeli","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.hjc.2018.09.004_bib24","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1200\/JCO.2004.09.109","article-title":"Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy","volume":"22","author":"Adams","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hjc.2018.09.004_bib25","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/pbc.23281","article-title":"Tissue Doppler evaluation of systolic and diastolic cardiac functions in long-term survivors of Hodgkin lymphoma","volume":"58","author":"Alehan","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.hjc.2018.09.004_bib26","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3109\/10428191003624249","article-title":"Comparative study of two mechlorethamine, vincristine, procarbazine, and prednisone derived chemotherapeutic protocols for the management of pediatric Hodgkin lymphoma (HL): single-center 5-year experience","volume":"51","author":"Al-Tonbary","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.hjc.2018.09.004_bib27","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S1470-2045(16)30215-7","article-title":"Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma: an analysis from the St Jude Lifetime Cohort Study","volume":"17","author":"Bhakta","year":"2016","journal-title":"Lancet Oncol"},{"issue":"36","key":"10.1016\/j.hjc.2018.09.004_bib28","doi-asserted-by":"crossref","first-page":"5735","DOI":"10.1200\/JCO.2006.05.6879","article-title":"Survival and late effects in children with Hodgkin's lymphoma treated with MOPP\/ABV and low-dose, extended-field irradiation","volume":"24","author":"Chow","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.hjc.2018.09.004_bib29","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/JCO.2002.12.101","article-title":"VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial","volume":"20","author":"Donaldson","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.hjc.2018.09.004_bib30","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1200\/JCO.2002.03.051","article-title":"Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation","volume":"20","author":"Friedmann","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hjc.2018.09.004_bib31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/00043426-200102000-00003","article-title":"Cyclophosphamide-based, seven-drug hybrid and low-dose involved field radiation for the treatment of childhood and adolescent Hodgkin disease","volume":"23","author":"Hamilton","year":"2001","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"22","key":"10.1016\/j.hjc.2018.09.004_bib32","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2004.02.139","article-title":"Risk-adapted, combined-modality therapy with VAMP\/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease","volume":"22","author":"Hudson","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.hjc.2018.09.004_bib33","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1200\/JCO.1998.16.11.3592","article-title":"Increased mortality after successful treatment for Hodgkin's disease","volume":"16","author":"Hudson","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hjc.2018.09.004_bib34","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/pbc.20213","article-title":"Evaluation of left ventricular function in long-term survivors of childhood Hodgkin disease","volume":"45","author":"Iarussi","year":"2005","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.hjc.2018.09.004_bib35","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/00043426-200606000-00008","article-title":"POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children's Oncology Group","volume":"28","author":"Kung","year":"2006","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"1","key":"10.1016\/j.hjc.2018.09.004_bib36","first-page":"61","article-title":"Signal-averaged electrocardiography in survivors of Hodgkin's disease treated with and without dexrazoxane","volume":"48","author":"Mladosievicova","year":"2001","journal-title":"Neoplasma"},{"issue":"Suppl 2","key":"10.1016\/j.hjc.2018.09.004_bib37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/annonc\/5.suppl_2.S113","article-title":"Hodgkin's disease in children: combined modality treatment for stages IA, IB, and IIA. Results in 356 patients of the German\/Austrian Pediatric Study Group","volume":"5","author":"Schellong","year":"1994","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.hjc.2018.09.004_bib38","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/pbc.22664","article-title":"Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies","volume":"55","author":"Schellong","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.hjc.2018.09.004_bib39","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00043426-199124000-00010","article-title":"Comparative effectiveness of two combined modality regimens in the treatment of surgical stage III Hodgkin's disease in children. An 8-year follow-up study by the Pediatric Oncology Group","volume":"13","author":"Sullivan","year":"1991","journal-title":"Am J Pediatr Hematol Oncol"},{"issue":"2","key":"10.1016\/j.hjc.2018.09.004_bib40","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/pbc.20546","article-title":"Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: a Pediatric Oncology Group (POG) study","volume":"46","author":"Tebbi","year":"2006","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.hjc.2018.09.004_bib41","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s00247-003-1114-3","article-title":"PET imaging in pediatric Hodgkin's lymphoma","volume":"34","author":"Hudson","year":"2004","journal-title":"Pediatr Radiol"},{"issue":"13","key":"10.1016\/j.hjc.2018.09.004_bib42","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.2011.34.8987","article-title":"Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group","volume":"30","author":"Blanco","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hjc.2018.09.004_bib43","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.hjc.2018.09.004_bib44","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.mayocp.2014.05.013","article-title":"Evaluation and management of patients with heart disease and cancer: cardio-oncology","volume":"89","author":"Herrmann","year":"2014","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.hjc.2018.09.004_bib45","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2014.56.1373","article-title":"Individual prediction of heart failure among childhood cancer survivors","volume":"33","author":"Chow","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hjc.2018.09.004_bib46","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1080\/10428190802140873","article-title":"Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy","volume":"49","author":"Myrehaug","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.hjc.2018.09.004_bib47","first-page":"827","article-title":"Adriamycin cardiotoxicity: a survey of 1273 patients","volume":"63","author":"Praga","year":"1979","journal-title":"Cancer Treat Rep"},{"issue":"1","key":"10.1016\/j.hjc.2018.09.004_bib48","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacc.2012.09.035","article-title":"Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy","volume":"61","author":"Thavendiranathan","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"36","key":"10.1016\/j.hjc.2018.09.004_bib49","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.hjc.2018.09.004_bib50","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"year":"2009","series-title":"N.C.I.,Common Terminology Criteria for Adverse Events","author":"NCI","key":"10.1016\/j.hjc.2018.09.004_bib51"},{"issue":"9","key":"10.1016\/j.hjc.2018.09.004_bib52","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J\u00a0Am Soc Echocardiogr"},{"issue":"3 Suppl 8","key":"10.1016\/j.hjc.2018.09.004_bib53","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1053\/j.seminoncol.2006.04.020","article-title":"Pathogenesis of cardiotoxicity induced by anthracyclines","volume":"33","author":"Elliott","year":"2006","journal-title":"Semin Oncol"},{"issue":"7","key":"10.1016\/j.hjc.2018.09.004_bib54","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0006-2952(98)00307-4","article-title":"A\u00a0critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin","volume":"57","author":"Gewirtz","year":"1999","journal-title":"Biochem Pharmacol"},{"issue":"17","key":"10.1016\/j.hjc.2018.09.004_bib55","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1161\/01.CIR.102.17.2105","article-title":"Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol","volume":"102","author":"Li","year":"2000","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hjc.2018.09.004_bib56","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.418","article-title":"Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers","volume":"8","author":"Henninger","year":"2017","journal-title":"Cell Death Dis"},{"issue":"12","key":"10.1016\/j.hjc.2018.09.004_bib57","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/heartjnl-2017-312103","article-title":"Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention","volume":"104","author":"Henriksen","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.hjc.2018.09.004_bib58","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-981-10-4304-8_8","article-title":"The Positive Effects of Exercise in Chemotherapy-Related Cardiomyopathy","volume":"1000","author":"Elena","year":"2017","journal-title":"Adv Exp Med Biol"},{"issue":"8","key":"10.1016\/j.hjc.2018.09.004_bib59","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1200\/JCO.2015.60.8851","volume":"34","author":"Asselin","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.hjc.2018.09.004_bib60","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.2014.59.4473","article-title":"Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group","volume":"33","author":"Chow","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.hjc.2018.09.004_bib61","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.biopha.2004.12.003","article-title":"Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients","volume":"59","author":"Galetta","year":"2005","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"10.1016\/j.hjc.2018.09.004_bib62","first-page":"CD003917","article-title":"Cardioprotective interventions for cancer patients receiving anthracyclines","author":"van Dalen","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.hjc.2018.09.004_bib63","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1470-2045(10)70301-6","article-title":"Should anthracyclines and dexrazoxane be used for children with cancer?","volume":"12","author":"van Dalen","year":"2011","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.hjc.2018.09.004_bib64","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.2015.61.7928","article-title":"Dexrazoxane in Children With Cancer: From Evidence to Practice","volume":"33","author":"Kremer","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"10.1016\/j.hjc.2018.09.004_bib65","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.2217\/fon-2018-0210","article-title":"Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling","volume":"14","author":"Reichardt","year":"2018","journal-title":"Future Oncol"},{"key":"10.1016\/j.hjc.2018.09.004_bib66","unstructured":"EMA. Questions and answers on Cardioxane (dexrazoxane, powder for solution for injection, 500 mg). Outcome of a procedure under Article 13 of Regulation (EC) No 1234\/2008. 2017; 19\/07\/2017:[Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Cardioxane_13\/WC500228103.pdf."},{"key":"10.1016\/j.hjc.2018.09.004_bib67","article-title":"Circulating microRNAs as novel biomarkers for heart failure","author":"Chen","year":"2017","journal-title":"Hellenic J Cardiol"},{"issue":"5","key":"10.1016\/j.hjc.2018.09.004_bib68","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.hjc.2017.03.006","article-title":"Serum Galectin-3 and ST2 as predictors of unfavorable outcome in stable dilated cardiomyopathy patients","volume":"58","author":"Wojciechowska","year":"2017","journal-title":"Hellenic J Cardiol"},{"issue":"3","key":"10.1016\/j.hjc.2018.09.004_bib69","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000455823","article-title":"Primary Prevention Strategies for Anthracycline Cardiotoxicity: A Brief Overview","volume":"62","author":"Menna","year":"2017","journal-title":"Chemotherapy"},{"year":"2018","series-title":"Cardiovascular Toxicity in Cancer Survivors: Current Guidelines and Future Directions","author":"Tan","key":"10.1016\/j.hjc.2018.09.004_bib70"}],"container-title":["Hellenic Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1109966618302999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1109966618302999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:12:39Z","timestamp":1761099159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1109966618302999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1109966618302999"],"URL":"https:\/\/doi.org\/10.1016\/j.hjc.2018.09.004","relation":{},"ISSN":["1109-9666"],"issn-type":[{"type":"print","value":"1109-9666"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Late-onset cardiomyopathy among survivors of childhood lymphoma treated with anthracyclines: a systematic review","name":"articletitle","label":"Article Title"},{"value":"Hellenic Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hjc.2018.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Hellenic Society of Cardiology. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}